BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10231728
• 负责人: Dandan Sun
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10231728
• 关键词: Achievement; Acute; Adult; Affect; Alanine; Alteplase; Animal Model; Antihypertensive Agents; Attenuated; Autopsy; Award; Behavioral; Brain; Brain Diseases; Brain Injuries; Cardiovascular Diseases; Carrier Proteins; Cause of Death; Cerebral Edema; Cerebrospinal Fluid; Cerebrovascular Disorders; Cognitive; Collaborations; Communication; Development; Disclosure; Disease; Edema; Exhibits; Free Radicals; Functional disorder; Funding; Grant; Health; Healthcare; Hemorrhage; High Prevalence; Homeostasis; Human; Hybrids; Hydrocephalus; Hypertension; Impairment; Inbred SHR Rats; Inbred WKY Rats; Inflammation; Inflammatory; International; Ion Transport; Ions; Ischemia; Ischemic Brain Injury; Ischemic Stroke; Kidney; Knockout Mice; Legal patent; Lysine; Maintenance; Malignant - descriptor; Mediating; Membrane; Microglia; Middle Cerebral Artery Infarction; Military Personnel; Mission; Modeling; Motor; Mus; NADPH Oxidase; Nature; Nervous System Physiology; Neuraxis; Neuroglia; Neuroprotective Agents; Oligodendroglia; Oxidative Stress; Pathogenesis; Patients; Pharmacology; Phenotype; Phosphorylation; Phosphotransferases; Play; Post-Traumatic Stress Disorders; Predisposition; Production; Proline; Protein Isoforms; Proteins; Rattus; Recovery of Function; Regulation; Reporting; Research; Research Project Grants; Rights; Role; Scientist; Sensorimotor functions; Signal Transduction; Sodium Chloride; Stroke; Structure of choroid plexus; Superoxides; Synapses; Technology Transfer; Therapeutic; Translational Research; Traumatic Brain Injury; United States Department of Veterans Affairs; Veterans; brain tissue; burden of illness; career; cell injury; chloride-cotransporter potassium; comorbidity; controlled cortical impact; cytokine; cytotoxic; disability; excitotoxicity; health care service; improved; improved outcome; inclusion criteria; inhibitor/antagonist; injury and repair; innovation; invention; macrophage; nervous system disorder; normotensive; novel; novel therapeutic intervention; pH Homeostasis; prehypertension; preservation; programs; protein expression; remyelination; scaffold; social; stroke intervention; stroke model; stroke therapy; therapeutic target; tissue repair; translational approach; white matter; white matter injury

PROJECT ABSTRACT Over the past 25 years, I have established an internationally renowned research program on studying membrane ion transport proteins and their functions in pathophysiology of neurological diseases. We have advanced our understanding about roles of ion transport proteins (Na+-K+-Cl- cotransporter, Na+/H+ exchanger and Na+/Ca2+ exchangers) in regulation of ionic homeostasis in the central nervous system under disease conditions such as acute ischemic stroke and traumatic brain injury (TBI). These brain disorders have high prevalence in veterans and our research is closely related to improving veterans’ health care, and the mission of VA BLRD. In the period of my RCS, I will conduct two research projects funded by BLR&D merit grants. Since I joined VAPHS as a Research Health Scientist in 2012, I have built broad collaborations with VA clinicians, VA scientists, and non- VA scientists. I currently serve as a Co-I on six collaborative projects with VA and non-VA scientists. I will continue to contribute my expertise to these collaborations. In the I01BX002891 study, we will investigate efficacy of SPAK inhibitor ZT-1a as a strategy for ischemic stroke therapy. Evolutionary conserved WNK ["with no lysine" (K)] kinases and the downstream SPAK/OSR1 (Ste20/SPS1-related proline/alanine-rich kinase and oxidative stress-responsive kinase 1) kinases regulate activities of multiple ion transporters and play important roles in renal salt handling, maintenance of arterial tone, and hypertension. Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) is one of the major substrates of the WNK- SPAK/OSR1 kinases. Stimulation of the WNK-SPAK kinases increased brain NKCC1 activity via protein phosphorylation and led to ischemic cell damage through NKCC1-mediated Na+ and Cl- overload, cytotoxic edema and excitotoxicity. In the initial funding period of BX002891 grant, we discovered that WNK-SPAK/OSR1 kinases are involved in the pathogenesis of ischemic stroke-induced brain damages (JCB&M. 2017). We concluded that augmented WNK-Cab39-NKCC1 signaling in hypertensive rats is associated with an increased susceptibility to ischemic brain damage and presents as a novel target for anti-hypertensive and anti-ischemic stroke therapy. We developed a novel WNK-SPAK inhibitor ZT-1a which shows robust neuroprotective activity in animal models of ischemic stroke (Nature Communications 2020). Derived from this research, a patent application (VA Invention Disclosure ID# 2018-313) “ Therapeutic application of ZT-1a and derivatives for brain disorders” has been filed via U.S. Department of Veterans Affairs. Assessing ZT-1a and its derivatives as novel neuroprotective drugs for acute ischemic stroke therapies is innovative and will benefit veterans’ health. In the second study funded by I01BX004625, we will investigate the roles of microglia-oligodendrocyte interactions in white matter injury and tissue repair and to explore glia-oriented therapeutic strategies for treating TBI. Microglia activation plays a role in white matter injury and tissue repair. Regulation of a switch between pro- inflammatory and adaptive phenotypes of microglia/macrophage is important for oligodendrocyte differentiation, remyelination, as well as remodeling of synapses. We recently discovered that Na/H exchanger isoform 1 protein (NHE1)-mediated H+ efflux maintains microglial intracellular pH homeostasis to promote NADPH oxidase activation, free radical superoxide production, and cytokine secretion. We reported that selective deletion of microglial Nhe1 in the Cx3cr1-CreER;Nheflox/flox (Nhe1 KO) mice preserved oligodendrocytes and improved sensorimotor function recovery in an experimental focal ischemic stroke model. Nhe1 KO mice exhibited increased APC+ mature oligodendrocyte counts and preserved white matter integrity in a controlled cortical impact-induced TBI model. Especially, post-TBI administration of the NHE1 protein inhibitor HOE642 accelerated neurological function recovery in mice after either stroke or TBI. We will further investigate NHE1 protein in modulating microglia-mediated inflammation in remyelination and tissue repair after TBI.

项目摘要 在过去的25年中，我建立了一项有关研究膜的国际知名研究计划 离子转运蛋白及其在神经系统疾病的病理生理学中的功能。我们已经提高了我们的 了解离子转运蛋白的作用（Na+-K+-cl- cotransporter，Na+/H+交换器和Na+/Ca2+ 在疾病条件下，在中枢神经系统中调节离子稳态的交换器） 急性缺血性中风和外伤性脑损伤（TBI）。这些脑部疾病在退伍军人中患病率很高 我们的研究与改善退伍军人的医疗保健以及VA Blrd的使命密切相关。在此期间 在我的RCS中，我将进行两个由Blr＆d优异赠款资助的研究项目。自从我加入vaphs以来 研究健康科学家于2012年与VA临床医生，VA科学家和非 - VA科学家。我目前在与VA和非VA科学家的六个合作项目中担任Co-I。我会 继续为这些合作贡献我的专业知识。 在I01BX002891研究中，我们将研究SPAK抑制剂ZT-1A的效率 治疗。进化配置了wnk [“无赖氨酸”（k）]激酶和下游spak/osr1 （Ste20/SPS1相关的脯氨酸/丙氨酸激酶和氧化应激反应性激酶1）激酶调节激酶 多个离子转运蛋白的活动，并在肾脏盐处理，维持动脉音调中起重要作用， 和高血压。 Na+-K+-2Cl-共转运蛋白同工型1（NKCC1）是WNK-的主要底物之一 SPAK/OSR1激酶。刺激 这 WNK-Spak激酶通过蛋白质增加了脑NKCC1活性 磷酸化并通过NKCC1介导的Na+和Cl-过载，细胞毒性导致缺血性细胞损伤 水肿和兴奋性。在BX002891赠款的最初资助期间，我们发现WNK-Spak/OSR1 激酶参与缺血性中风引起的脑损伤的发病机理（JCB＆m。2017）。我们 结论是高血压大鼠中增强的WNK-CAB39-NKCC1信号传导与增加有关 对缺血性脑损伤的敏感性，并将其作为抗高血压和抗异流的新目标 中风疗法。我们开发了一种新型的WNK-Spak抑制剂ZT-1A，该抑制剂显示出强大的神经保护活性 在缺血性中风的动物模型中（自然通讯2020）。源自这项研究，专利 申请（VA发明披露ID＃2018-313）” ZT-1A的治疗应用和大脑的衍生物 疾病” 已通过美国退伍军人事务部提交。评估ZT-1A及其衍生物作为新颖 急性缺血性中风疗法的神经保护药是创新的，将使退伍军人的健康受益。 在由I01BX004625资助的第二项研究中，我们将研究小胶质细胞 - 寡胶质细胞的作用 白质损伤和组织修复方面的相互作用，并探索以神经胶质为导向的治疗策略 TBI。小胶质细胞激活在白质损伤和组织修复中起作用。调节pro-之间的切换 小胶质细胞/巨噬细胞的炎症和适应性表型对于少突胶质细胞分化很重要， 再髓以及突触的重塑。我们最近发现Na/H交换器同工型1蛋白 （NHE1）介导的H+外排保持小胶质细胞内pH稳态以促进NADPH氧化酶 激活，自由基超氧化物产生和细胞因子分泌。我们报告了选择性删除 CX3CR1-CREER中的小胶质细胞NHE1； NHEFLOX/FLOX（NHE1 KO）小鼠保留了少突胶质细胞并改善 实验性局灶性缺血性中风模型中的感觉运动功能恢复。 NHE1 KO小鼠暴露 增加的APC+成熟的少突胶质细胞计数并保留在受控皮质中的白质完整性 撞击引起的TBI模型。特别是，TBI后NHE1蛋白抑制剂HOE642加速了 中风或TBI后小鼠的神经功能恢复。我们将进一步研究NHE1蛋白 调节小胶质细胞介导的炎症在TBI后的透明度和组织修复中。